MedGenome launches personalised genomic test for cancer in India

MedGenome, India’s leading genomics‑driven diagnostics and research services company has launched OncoTrack MRD, a personalised and ultrasensitive NGS-based tumour‑informed Molecular Residual Disease (MRD) test in the country.

OncoTrackMRD is a comprehensive, personalised, tumour-informed, molecular residual disease test for patients previously diagnosed with cancer. Tailored to each patient using their own tumour tissue, the test analyzes circulating tumour DNA to detect and measure residual cancer, identify potential recurrence earlier than conventional methods, and support treatment decisions. Developed in-house, its ultra-sensitive approach is designed to track tumour-specific signals, instead of relying on a generic set of mutations.

OncoTrack MRD enables clinicians to monitor relapse throughout the course of cancer care through a simple, repeatable blood test that can be performed multiple times a year, as clinically appropriate. By tracking changes in tumor DNA over time, it provides insights into residual disease and treatment response and can help identify the risk of recurrence earlier. With convenient home sample collection and nationwide availability, OncoTrack MRD enables accessible, longitudinal monitoring for patients across India.

“The cancer burden has been steadily increasing in India with roughly about 1.5 million new cases annually and one of the biggest challenges for oncologists is identifying patients who may be at risk of recurrence even when there are no visible signs of disease. For many cancer survivors, the wait between scans can be filled with uncertainty. The possibility of recurrence remains a concern; Did the treatment work? Is there any cancer left? Could it be coming back? Our personalised and ultrasensitive NGS based tumour‑informed MRD test answers these questions by adding an important layer of molecular insight to complement existing clinical assessment and imaging," Vedam Ramprasad, CEO, MedGenome said. “OncoTrack MRD reflects our continued commitment to Make in India for the world by making global quality advanced precision oncology affordable and accessible to patients and clinicians across the country," he added.

The company claims that OncoTrack MRD can be applied across a broad range of solid tumours, including breast, colorectal, lung, ovarian and other gynaecological cancers, pancreatic, oesophageal, gastric, hepatocellular and thoracic cancers, as well as melanoma. It is particularly suited for patients with resected Stage II/III colorectal cancer, early‑stage non‑small cell lung cancer (NSCLC), and early or locally advanced breast cancer who have completed curative‑intent treatment, they said.

"While imaging remains an essential part of cancer follow up, microscopic disease can sometimes remain undetected until it progresses. Tumour informed MRD testing offers clinicians a powerful tool to identify patients who may require closer surveillance or timely intervention, supporting a more personalised approach to cancer care," Dr. Niti Raizada, Principal Director-Medical Oncology, Fortis Hospitals said.